Clinical Research Of Curative Effect And Short-term Prognosis Of Xinmailong Injection In The Treatment Of The Patients With Chronic Heart Failure

Objective: To initially explore value of clinic application of Xinmailong injection by observing curative effect and related indexes of prognosis of Xinmailong injection combined with conventional medicine treating the patients with chronic heart failure,and its advantages in the treatment of the patients with chronic heart failure compared with conventional medicine.Methods: A total of 42 cases of patients with chronic heart failure from March 2016 to November 2016 treated in the Third Ward of department of cardiology of the second affiliated hospital of Kunming medical university in the hospital who met grouping criteria, were randomly divided into conventional treatment group (n=21)and Xinmailong treatment group (n=21) according to random number table. Both groups were given standard conventional medicine treatment, on the basis of which the Xinmailong group was treated by Xinmailong injection combined with conventional medicine treatment. And left ventricular ejection fraction, N-terminal pro-Brain Naturetic Peptide and 6-minute walk distance and NYHA cardiac function classification were recorded respectively before treatment, five days after the treatment and during the first and third month of follow-up. And adverse drug reactions during hospitalization period were observed. Minnesota Living With Heart Failure Questionnaire scores of each group were collected before the treatment, and during the first and third month of follow-up respectively. Each group of patients was followed up for 3 months to observe main adverse cardiac events in patients. All of data was processed by statistical analysis.Results: 1. There were no significant differences between the two groups in comparing baseline information such as age (t=0.145,P=0.885),course of disease(t=0.990,P=0.328),gender (?2=0.099,P=0.753),basic heart disease (x~2=0.492,P=0.847),state of illness (?2=0.110,P=0.946) (all P>0.05).2. Comparison of left ventricular ejection fraction (LVEF): there was no significant difference between the two groups in comparing LVEF before the treatment, but all scores of LVEF in each group after the treatment, during the first and third month of follow-up have raised (P<0.05), and which of the Xinmailong group increased higher than that of the conventional treatment group (P<0.05).3. Comparison of N-terminal pro-Brain Naturetic Peptide (NT-proBNP): there was no significant difference between the two groups in comparing NT-proBNP before the treatment, but all scores of NT-proBNP in each group after the treatment, during the first and third month of follow-up have lowered (P<0.05), and which of the Xinmailong group decreased more obviously than that of the conventional treatment group (P<0.05).4.Comparison of 6-minute walk distance(6MWD): there was no significant difference between the two groups in comparing scores of 6MWD before the treatment, but all scores of 6MWD in each group after the treatment, during the first and third month of follow-up have increased (P<0.05), and which of the Xinmailong group increased higher than that of the conventional treatment group (P<0.05).5. Comparison of the improvement of NYHA cardiac function classification: The NYHA cardiac function classification obvious effective rate of the Xinmailong group(61.90%) was higher than that of the conventional treatment group (19.05%), and there was a significant difference between the two groups (x~2=8.005, P=0.005).6. Observation of liver and kidney function, platelet and hemoglobin in two groups:There was one case of patients with thrombocytopenia in the Xinmailong group, and the remaining patients did not appear obvious adverse reaction during the treatment.There were no differences before and after the treatment in comparing indexes such as liver function, platelet and hemoglobin of the two groups (P>0.05). There was no significant difference between the two groups in comparing creatinine before the treatment, but all the level of creatinine in each group have reduced after the treatment(P<0.001), and which of the Xinmailong group reduced more significantly than that of the conventional treatment group (P<0.05).7. Comparison of Minnesota Living With Heart Failure Questionnaire (MLHFQ)scores: there was no significant difference between the two groups in comparing MLHFQ scores before the treatment, but all scores of MLHFQ in each group have reduced during the first and third month of follow-up (P<0.05), and which of the Xinmailong group reduced lower than that of the conventional treatment group(P<0.05).8. Comparison of incidence of main adverse cardiac events (MACE) after 1 and 3 months: During the third month of follow-up, incidence of adverse cardiac events of the Xinmailong group (14.29%) was lower than that of the conventional treatment group(42.86%) with significant difference (?2=4.200; P=0.04).Conclusions: 1. There was a certain curative effect of Xinmailong injection in the treatment of the patients with chronic heart failure and its effect of which was synergistic with the current guidelines recommend treatments. 2. Xinmailong injection might improve the quality of life and short-term prognosis of patients with chronic heart failure.